Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $59.00

Enliven Therapeutics (NASDAQ:ELVN) had its target price lifted by The Goldman Sachs Group from $41.00 to $59.00 in a research note released on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms have also recently weighed in on ELVN. Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. HC Wainwright boosted their target price on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Finally, Mizuho raised their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday, March 25th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.80.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $40.75 on Friday. The business’s 50-day moving average is $37.05 and its two-hundred day moving average is $27.33. The firm has a market capitalization of $2.48 billion, a PE ratio of -24.40 and a beta of 0.32. Enliven Therapeutics has a 12 month low of $14.78 and a 12 month high of $48.53.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. Equities analysts anticipate that Enliven Therapeutics will post -1.7 EPS for the current year.

Insider Buying and Selling

In related news, CFO Benjamin Hohl sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the sale, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at approximately $1,508,580. This represents a 16.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Richard A. Heyman sold 1,230 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total value of $32,201.40. Following the transaction, the director owned 22,647 shares in the company, valued at $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 25.90% of the company’s stock.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ELVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Enliven Therapeutics by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after buying an additional 1,693 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Enliven Therapeutics by 61.3% during the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after acquiring an additional 80,506 shares during the period. Jane Street Group LLC bought a new position in Enliven Therapeutics in the first quarter worth about $578,000. Legal & General Group Plc lifted its holdings in Enliven Therapeutics by 52.2% in the second quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock worth $646,000 after acquiring an additional 11,058 shares during the last quarter. Finally, Quantbot Technologies LP boosted its stake in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after acquiring an additional 1,434 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.